STAT3 and non-small cell lung carcinoma: Additionally, recombinant IL-6 (rIL-6), but not rIL-8 enhanced the production of both cytokines (Figure 6D) by activating AKT, STAT3 and NF-κB pathways (Figure 6E), indicating that an IL-6/NF-κB inflammatory loop is activated in aggressive NSCLC cells as illustrated in Figure 6F.